logo

OncoTrials - мониторинг клинических исследований

Новые исследования (2025-02-13):

NCT06821880 (Множественная миелома)
NCT06821880 (Хронический лимфолейкоз | Лимфома из малых лимфоцитов)
NCT06822829 (Диффузная крупноклеточная В-клеточная лимфома)
NCT06823960 (Лимфома маргинальной зоны)


Найдено исследований: 14

NCT06821880 (добавлено:  Сегодня! )

Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project

Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project

Теги:  #Plasma cell leukemia 

Локации: BKH Kufstein; Kufstein; Austria,Klinikum Garmisch-Partenkirchen; Garmisch-Partenkirchen; Germany,Medizinische Universität Graz; Graz; Austria,Medizinische Universität Innsbruck; Innsbruck; Tyrolia; Austria,Onkologischer Schwerpunkt am Oskar-Helene-Heim; Berlin; Germany

NCT06676033 (добавлено: 2025-02-05)

Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome

Correlative Study of Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome

Локации: National Institutes of Health Clinical Center; Bethesda; Maryland; United States

NCT06697184 (добавлено: 2025-02-04)

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies.

Локации: Blacktown Cancer and Haematology Centre; Blacktown; New South Wales; Australia,Chu Dijon; Dijon; France,Chu Montpellier Hopital Saint Eloi; Montpellier Cedex; France,Dana Farber Cancer Institute; Boston; Massachusetts; United States,Fort Wayne Medical Oncology and Hematology; Fort Wayne; Indiana; United States,Fred Hutchinson Cancer Research Center; Seattle; Washington; United States,Hopital Avicenne, Aphp, Bobigny; Bobigny; France,Hopital Larchet Chu Nice; Nice; France,Iuct Oncopole; Toulouse Cedex; France,Linear Clinical Research; Nedlands; Western Australia; Australia,Moffitt Cancer Center; Tampa; Florida; United States,Queen Elizabeth Hospital; Birmingham; United Kingdom,Rockingham Hospital; Cooloongup; Western Australia; Australia,St Jamess University Hospital; Leeds; United Kingdom,The Alfred Hospital; Melbourne; Victoria; Australia,The Christie Nhs Foundation Trust Manchester; Manchester; United Kingdom,The University of Kansas Cancer Center; Westwood; Kansas; United States,University Hospitals Bristol

NCT06588478 (добавлено: 2025-01-15)

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor

Теги:  #Relapsed|Refractory 

Локации: A.O.U.C. Policlinico di Bari; Bari; Puglia; Italy,Aarhus Universitetshospital, Skejby; Aarhus; Midtjylland; Denmark,AIDPORT Sp. z o.o.; Skórzewo; Wielkopolskie; Poland,American Oncology Partners of Maryland, PA; Bethesda; Maryland; United States,Ankara University Health Practice and Research Hospitals; Ankara; Turkey,AO Santa Maria della Misericordia; Perugia; Umbria; Italy,AOU Policlinico Umberto I; Roma; Italy,ASST Grande Ospedale Metropolitano Niguarda; Milan; Lombardia; Italy,Attikon General University Hospital; Chaidari; Attikí; Greece,AZ Delta vzw; Roeselare; West-Vlaanderen; Belgium,AZ Nikolaas; Sint-Niklaas; Oost-Vlaanderen; Belgium,AZ Sint-Jan Brugge-Oostende AV; Brugge; West-Vlaanderen; Belgium,Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO; Palermo; Sicilia; Italy,Azienda Ospedale - Università Padova; Padova; Veneto; Italy,Azienda Ospedaliera Universitaria Careggi; Firenze; Toscana; Italy,Azienda Ospedaliero Universitaria Maggiore della Carità; Novara; Italy,Azienda Ospedaliero Universitaria S.

NCT06761586 (добавлено: 2025-01-08)

A Study of AUR104 in Patients with Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)

A Phase 1, Open Label, Dose Escalation, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Oral AUR104 in Patients with Select Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)

Теги:  #Relapsed|Refractory 

Локации: Adwaita Cancer Hospital & ICU; Surat; Gujarat; India,Kiran Multi Super Speciality Hospital and Research Centre; Surat; Gujarat; India,Kolhapur Cancer Centre Pvt. Ltd.; Kolhapur; Maharashtra; India,MMFHA Joshi Hospital; Pune; Maharashtra; India,Sunshine Global Hospitals; Surat; Gujarat; India

NCT06208735 (добавлено: 2025-01-07)

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

CLIC-02: A Phase I Trial of CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Теги:  #Relapsed|Refractory 

Локации: Alberta Children`s Hospital; Calgary; Alberta; Canada,BC Children`s Hospital; Vancouver; British Columbia; Canada,Calgary Cancer Centre; Calgary; Alberta; Canada,Princess Margaret Cancer Centre; Toronto; Ontario; Canada,The Hospital for Sick Children; Toronto; Ontario; Canada,The Ottawa Hospital - General Campus; Ottawa; Ontario; Canada,Vancouver General Hospital; Vancouver; British Columbia; Canada

NCT06528301 (добавлено: 2024-12-10)

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

A Phase 1, Multicenter, Open-label Study of UB-VV111 in Combination With Rapamycin in Relapsed/Refractory (R/R) CD19+ B-cell Malignancies

Теги:  #Relapsed|Refractory 

Локации: City of Hope; Duarte; California; United States,University of Nebraska Medical Center; Omaha; Nebraska; United States,Washington University School of Medicine/Siteman Cancer Center; Saint Louis; Missouri; United States

NCT06637501 (добавлено: 2024-11-30)

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia

Теги:  #Newly diagnosed 

Локации: Aoor Villa Sofia Cervello; Palermo; Italy,Aou Careggi, Servizio Sanitario Toscana; Firenze; Italy,Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia; Brescia; Italy,Centro de Pesquisas Oncologicas Cepon; Florianopolis; Brazil,Cleveland Clinic Florida; Weston; Florida; United States,Clinica Universidad de Navarra Pamplona; Pamplona; Spain,Clinica Universidad de Navarra; Madrid; Spain,Fujian Medical University Union Hospital; Fuzhou; Fujian; China,Henan Cancer Hospital; Zhengzhou; Henan; China,Hospital Clinic de Barcelona; Barcelona; Spain,Hospital de Cabuenes; Gijon; Spain,Hospital de Clínicas de Porto Alegre; Porto Alegre; Brazil,Hospital de Clinicas de Porto Alegre; Porto AlegreRS; Brazil,Illinois Cancer Specialists (Niles) Usor; Niles; Illinois; United States,Instituto Dor de Pesquisa E Ensino Sao Paulo; Sao Paulo; Brazil,Jiangsu Province Hospital; Nanjing; Jiangsu; China,Nebraska Cancer Specialists (Satellite Site); Grand Island; Nebraska; United States,Nebraska Cancer Specialists; Grand

NCT06662227 (добавлено: 2024-10-31)

Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

A Clinical Study Evaluating the Safety and Efficacy of Universal CD19-Targeted CAR-T (UWD-CD19) Therapy for Refractory and Relapsed B-Cell Tumors

Теги:  #Relapsed|Refractory 

Локации: The First Affiliated Hospital of University of Science and Technology of China; Hefei; Anhui; China

NCT06544785 (добавлено: 2024-10-25)

Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Multicenter, Phase 2 Randomized, Open Label Study to Evaluate Zanubrutinib in Combination With Obinutuzumab in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (GELLC-10-ZANUBIO)

Теги:  #Newly diagnosed 

Локации: H. Vall d`Hebrón; Barcelona; Spain

NCT06364423 (добавлено: 2024-10-15)

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Phase I/II Trial of Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Теги:  #Relapsed|Refractory 

Локации: National Institutes of Health Clinical Center; Bethesda; Maryland; United States

NCT06466122 (добавлено: 2024-10-15)

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients with CLL or SLL Resistant to Covalent BTKi

Phase 2 Study of Combination Pirtobrutinib (LOXO-305) and Venetoclax in CLL Patients with Resistance to Covalent BTKi

Локации: Ohio State University Comprehensive Cancer Center; Columbus; Ohio; United States

NCT06542250 (добавлено: 2024-10-15)

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (TITANium)

Теги:  #Relapsed|Refractory 

Локации: Research Site; Barcelona; Spain,Research Site; Bologna; Italy,Research Site; Boston; Massachusetts; United States,Research Site; Calgary; Alberta; Canada,Research Site; Charlotte; North Carolina; United States,Research Site; Chuo-ku; Japan,Research Site; Concord; North Carolina; United States,Research Site; Hackensack; New Jersey; United States,Research Site; Hangzhou; China,Research Site; Houston; Texas; United States,Research Site; Kashiwa; Japan,Research Site; København Ø; Denmark,Research Site; L`Hospitalet de Llobregat; Spain,Research Site; La Jolla; California; United States,Research Site; Madrid; Spain,Research Site; Melbourne; Australia,Research Site; Milano; Italy,Research Site; Montreal; Quebec; Canada,Research Site; München; Germany,Research Site; Nedlands; Australia,Research Site; New York; New York; United States,Research Site; Pessac; France,Research Site; Seattle; Washington; United States,Research Site; Shanghai; China,Research Site; Toronto; Ontario; Canada,Research Site; Ulm; Germany,Rese

NCT06343376 (добавлено: 2024-05-19)

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

A Phase I Trial of CD19-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells Genetically Engineered to Secrete Interleukin 12 (IL-12) and With a Truncated Human Epidermal Growth Factor Receptor (EGFRt) in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies

Теги:  #Relapsed|Refractory 

Локации: Roswell Park Cancer Institute, Buffalo, New York, United States,Roswell Park Cancer Institute; Buffalo; New York; United States